Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Common Equity (2016 - 2026)

Orthofix Medical has reported Common Equity over the past 18 years, most recently at $435.2 million for Q1 2026.

  • For the quarter ending Q1 2026, Common Equity fell 5.04% year-over-year to $435.2 million, compared with a TTM value of $435.2 million through Mar 2026, down 5.04%, and an annual FY2025 reading of $450.0 million, down 10.55% over the prior year.
  • Common Equity came in at $435.2 million for Q1 2026, down from $450.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $664.2 million in Q1 2023 to a low of $333.5 million in Q3 2022.
  • Median Common Equity over the past 5 years was $458.3 million (2025), compared with a mean of $485.6 million.
  • The sharpest move saw Common Equity surged 97.92% in 2023, then fell 19.64% in 2025.
  • Over 5 years, Common Equity stood at $336.9 million in 2022, then surged by 77.74% to $598.7 million in 2023, then fell by 15.97% to $503.1 million in 2024, then fell by 10.55% to $450.0 million in 2025, then fell by 3.3% to $435.2 million in 2026.
  • Per Business Quant, the three most recent readings for OFIX's Common Equity are $435.2 million (Q1 2026), $450.0 million (Q4 2025), and $442.5 million (Q3 2025).